 LEXINGTON, Mass.--BUSINESS WIRE--Aldeyra Therapeutics, Inc. Nasdaq: ALDX Aldeyra today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. ET to report top-line results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 methotrexate injection, United States Pharmacopeia for intravitreal administration in patients with proliferative vitreoretinopathy PVR, a rare, sight-threatening ocular disease with no approved therapy. The dial-in numbers 